#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16036	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2074	768.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1674	1674	T	936	T,C	865,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16036	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2074	768.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1408	1408	C	901	C	864	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	16036	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2074	768.8	0	HET	.	.	.	A69G	.	69	69	A	293	293	A	868	A,G	463,340	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29092	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3557	815.3	0	.	n	.	0	C1176T	SNP	1176	1176	C	1449	1449	T	919	T,C	866,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29092	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3557	815.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1610	1610	A	1001	A	940	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29092	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3557	815.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2244	2244	C	974	C	904	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29092	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3557	815.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2318	2318	A	957	A	895	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29092	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3557	815.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2870	2870	C	881	C,T	828,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2264	folP	852	852	99.88	folP.l15.c4.ctg.1	1407	160.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	711	713	AAA	218;218;217	A;A;A	204;202;203	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	539	2264	folP	852	852	99.88	folP.l15.c4.ctg.1	1407	160.1	1	SNP	p	R228S	1	.	.	682	684	AGC	942	944	AGC	244;241;241	A;G,T;C	229;226,1;230	folP.WHO_N_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6018	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3143	190.0	0	.	p	.	0	K261del	DEL	781	781	A	973	973	A	198	A	190	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6018	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3143	190.0	1	SNP	p	S91F	0	.	.	271	273	TCC	463	465	TCC	193;193;196	T;C;C	176;177;177	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6018	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3143	190.0	1	SNP	p	D95G	0	.	.	283	285	GAC	475	477	GAC	182;180;182	G;A;C	166;163;168	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	6018	gyrA	2751	2751	99.89	gyrA.l15.c17.ctg.1	3143	190.0	1	SNP	p	D95N	0	.	.	283	285	GAC	475	477	GAC	182;180;182	G;A;C	166;163;168	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1884	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1261	148.2	1	SNP	p	G45D	0	.	.	133	135	GGC	470	472	GGC	249;248;247	G;G;C,G	235;235;230,1	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1050	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	891	116.8	0	.	n	.	0	A197.	DEL	197	197	A	489	489	A	252	A	240	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5758	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2907	197.4	1	SNP	p	D86N	0	.	.	256	258	GAC	558	560	GAC	221;224;223	G;A;C	210;213;213	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5758	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2907	197.4	1	SNP	p	S87R	0	.	.	259	261	AGT	561	563	AGT	221;222;223	A;G;T	209;212;211	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5758	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2907	197.4	1	SNP	p	S87W	0	.	.	259	261	AGT	561	563	AGT	221;222;223	A;G;T	209;212;211	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5758	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2907	197.4	1	SNP	p	S87I	0	.	.	259	261	AGT	561	563	AGT	221;222;223	A;G;T	209;212;211	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5758	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2907	197.4	1	SNP	p	S88P	0	.	.	262	264	TCC	564	566	TCC	221;224;228	T;C;C	211;216;219	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4674	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2678	174.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1524	1526	GGC	208;208;200	G;G;C	195;197;184	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1165	1167	GCA	250;249;248	G;C,A;A	236;230,1;233	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1168	1170	ATC	249;249;250	A;T;C	236;238;235	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1180	1182	GTG	243;242;241	G;T;G	226;226;223	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1180	1182	GTG	243;242;241	G;T;G	226;226;223	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1684	1686	ACC	238;241;242	A;C;C	213;225;226	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1738	1740	GCG	216;218;216	G;C,G;G	197;174,1;183	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1738	1740	GCG	216;218;216	G;C,G;G	197;174,1;183	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1861	1863	GGC	226;227;228	G;G;C,A	209;211;206,1	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1870	1872	GGC	220;220;217	G;G;C	199;201;200	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4638	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2275	202.4	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1888	1890	CTG	200;202;203	C,G;T;GCCC,GCCCC	155,1;140;155,2	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6652	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2920	226.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1575	1577	CCG	270;268;267	C;C;G	245;251;242	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2408	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1687	141.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	552	552	C	142	C	133	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	396	398	GAA	278;278;277	G;A;A	261;264;265	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	684	686	GAT	280;281;283	G,T;A;T	264,1;268;265	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	807	809	TCA	287;289;292	T;C;A	259;264;265	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	D212N	NONSYN	634	636	GAT	918	920	AAT	278;277;277	A;A;T,A	263;262;256,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	936	938	GTC	275;271;270	G;T;C	262;255;259	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	F222S	NONSYN	664	666	TTT	948	950	TCT	277;276;276	T;C,G;T,C	260;257,1;254,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1266	1268	GCA	226;227;231	G;C,A;A	213;212,1;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	1	SNP	p	G120K	1	.	.	358	360	AAG	642	644	AAG	260;261;263	A;A;G	246;244;243	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	1	SNP	p	A121D	1	.	.	361	363	GAC	645	647	GAC	262;259;260	G;A;C	243;240;243	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3268	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1473	220.6	1	SNP	p	D121N	0	.	.	361	363	GAC	645	647	GAC	262;259;260	G;A;C	243;240;243	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	11992	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4892	244.5	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1956	1958	AAT	259;260;255	A;A;T	247;246;240	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1340	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	973	136.5	1	SNP	p	V57M	1	.	.	169	171	ATG	466	468	ATG	281;277;275	A;T;GAA,GA	266;260;264,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
